Loading stock data…
MRK
$109.18-1.77 (-1.60%)
Pre-Market$110.88+1.70 (+1.56%)· Last close Apr 30
Merck & Co., Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck & Co., Inc. in the Healthcare sector is trading at $109.18. The stock is currently 13% below its 52-week high of $125.14, remaining 10.7% above its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why MRK maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$109.18
Potential Upside
56.3%
Whystock Fair Value$170.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$129.74+18.8%
Range$100.00 – $150.00
Fundamentals
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bri...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$279.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.51
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
302.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.19%
Volume
Today's trading volume
12.28M
Recent News
Amgen's Numbers Are Out: It Gets To Keep Its Cholesterol Crown — For Now
Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
Dow Jones' Merck Tops Forecasts, But Growth Products Come Up Mixed
Merck easily topped expectations Thursday, delivering lighter-than-expected losses as Keytruda handily beat sales forecasts.
Merck Sales Beat As Winrevair Hits $525 Million
Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
Merck First-Quarter Sales Rise on Continued Keytruda Growth
The company’s quarterly sales rose 5% to $16.29 billion, boosted by 12% growth for its flagship Keytruda cancer drug.